KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma
This dual-targeted therapeutic strategy holds promises for overcoming the challenges posed by KRAS-driven cancers, particularly in addressing the formidable obstacle of pancreatic cancer.
Authors
- Nelson Dusetti (ORCID: https://orcid.org/0000-0002-6161-8483)
- Raúl Urrutia (ORCID: https://orcid.org/0000-0002-1640-6780)
- Eduardo Chuluyán (ORCID: https://orcid.org/0000-0003-3084-2500)
- Patricia Santofimia‐Castaño (ORCID: https://orcid.org/0000-0003-2506-5567)
- Matías Estarás (ORCID: https://orcid.org/0000-0003-3462-7904)
- Nicolás A. Fraunhoffer (ORCID: https://orcid.org/0000-0003-1561-2563)
- Daniel Grasso (ORCID: https://orcid.org/0000-0002-8932-716X)
- Gwen Lomberk (ORCID: https://orcid.org/0000-0001-5463-789X)
- Juan Iovanna (ORCID: https://orcid.org/0000-0003-1822-2237)
- Analía Meilerman Abuelafia
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Medical College of Wisconsin (US)
- Universidad de Buenos Aires (AR)
- Centre de Recherche en Cancérologie de Marseille (FR)
Publication Details
- Journal
- Translational Oncology
- Published
- 2025-05-17
- DOI
- https://doi.org/10.1016/j.tranon.2025.102421
- Citations
- 1
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Centre de Recherche en Cancérologie de Marseille
- Institut National de la Santé et de la Recherche Médicale
- Institut National Du Cancer